+
Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility
ECONOMY & POLICY

Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility

Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.

The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.

In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.

Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.

Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.

News source: The Hindu


Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.News source: The Hindu

Next Story
Infrastructure Transport

East-West Metro’s Esplanade-Sealdah Stretch Set To Open

The long-awaited East-West Metro is finally set to begin operations, with the 2.5-km Esplanade-Sealdah stretch ready for inauguration. The section, completed in late April, has been awaiting passenger services since then.Satish Kumar, Chairman and CEO of the Railway Board, inspected the corridor on Tuesday along with two other metro routes. He travelled between Howrah and Sealdah on the Green Line, from Noapara to Jai Hind Bimanbandar (Airport) on the Yellow Line, and between Ruby and Beleghata on the Orange Line. Kumar emphasised that the railways are committed to upholding the highest standa..

Next Story
Infrastructure Transport

Paras Railtech Wins Rs 1.22 Billion Mumbai Metro Contract

Paras Railtech Private Limited has received the Letter of Acceptance (LoA) for the second ballastless track contract, Package CA-273, of Mumbai Metro Line 2B (Yellow Line). The 23.6-km corridor runs between Andheri West and Mandale.The Mumbai Metropolitan Region Development Authority (MMRDA) had floated the tender in March 2025 with an estimated value of Rs 1.22 billion. Technical bids were opened on 22 April, with three firms submitting offers. Following technical evaluation on 14 May, two bids were rejected during the financial assessment. Paras Railtech was declared the lowest bidder and on..

Next Story
Infrastructure Urban

Agartala Smart City Projects Worth Rs 8.44 Billion Progressing

Agartala Smart City Limited is currently executing projects worth over Rs 8.44 billion and has set a target to complete storm water drain and road works before Durga Puja this year.According to Chief Executive Officer Dr Shailesh, the organisation has taken up 65 projects, all of which have been completed. Among the major works, the city addressed long-standing problems of waterlogging and flooding. To resolve this, 24 projects worth Rs 646 million were implemented, which included the installation of six new flood pumps. Storm water drains were also redesigned to ensure easier cleaning.For mai..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?